Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo

These studies compared the efficacies of our clinical agent galeterone (Gal) and the FDA-approved prostate cancer drug, enzalutamide (ENZ) with two lead next generation galeterone analogs (NGGAs), VNPP414 and VNPP433-3β, using prostate cancer (PC) in vitro and in vivo models. Antitumor activities of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwegyir-Afful, Andrew K., Ramalingam, Senthilmurugan, Ramamurthy, Vidya P., Purushottamachar, Puranik, Murigi, Francis N., Vasaitis, Tadas S., Huang, Weiliang, Kane, Maureen A., Zhang, Yuji, Ambulos, Nicholas, Tiwari, Sudhir, Srivastava, Pratima, Nnane, Ivo P., Hussain, Arif, Qiu, Yun, Weber, David J., Njar, Vincent C. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895912/
https://www.ncbi.nlm.nih.gov/pubmed/31653008
http://dx.doi.org/10.3390/cancers11111637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895912/
https://www.ncbi.nlm.nih.gov/pubmed/31653008
http://dx.doi.org/10.3390/cancers11111637

Ejemplares similares